Murepavadin

DB14777InvestigationalSmall molecule

Murepavadin is under investigation in clinical trial NCT02110459 (Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment).

Formula / weight: C₇₃H₁₁₂N₂₂O₁₆ · 1553.837 g/mol (avg)
Code names: POL7080

Resolves to

Compound

UNII0D02GRY87ZCAS944252-63-5ChEMBLCHEMBL3946483

Structure

InChIKeyRIDRXGOBXZLKHZ-NZUANIILSA-NSMILES

CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCCN)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O

Targets

Q96LB1MRGPRX2

What you can answer from here — as of September 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

56Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Murepavadin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account